Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 3 of 3 for “"Trastuzumab-Resistance"”.

  1. Mdm2-Mediated Degradation of Sirt6 Phosphorylated By Akt1 Promotes Tumorigenesis and Trastuzumab Resistance In Breast Cancer

    … vivo.</em> In addition, knockdown of SIRT6 in trastuzumab-sensitive cells renders them resistant to trastuzumab whereas overexpression of phosphorylation defective SIRT6 mutant restores trastuzumab sensitivity in the resistant cells. Thus, activation or re-expression of SIRT6 has potential …

    uthsc Repository record for Mdm2-Mediated Degradation of Sirt6 Phosphorylated By Akt1 Promotes Tumorigenesis and Trastuzumab Resistance In Breast Cancer (opens in a new tab)

  2. Jab1 Negatively Regulates Pten and Promotes Resistance to Trastuzumab In Her2-Positive Breast Cancer

    … approximately 20% of all breast cancer cases. Trastuzumab (Herceptin), the first targeted therapy approved for HER2-positive disease, potently prevents the activation of signaling pathways downstream of HER2 and significantly improves patients’ outcomes. However, resistance to trastuzumab is …

    uthsc Repository record for Jab1 Negatively Regulates Pten and Promotes Resistance to Trastuzumab In Her2-Positive Breast Cancer (opens in a new tab)

  3. Development and Evaluation of Novel Anti-HER2 Theranostics Against HER2-Positive Breast Cancer

    … and approval of anti-HER2 monoclonal antibody trastuzumab which is now the standard of care treatment. However, the disease relapses in almost all patients. As a result, alternative HER2-targeted therapies, such as pertuzumab, margetuximab, T-DM1, T-DXd, lapatinib, neratinib, pyrotinib, …

    sask Repository record for Development and Evaluation of Novel Anti-HER2 Theranostics Against HER2-Positive Breast Cancer (opens in a new tab)